News Releases

November 7, 2022
SEATTLE --(BUSINESS WIRE)--Nov. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results
September 20, 2022
SEATTLE --(BUSINESS WIRE)--Sep. 20, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of
Displaying 1 - 10 of 32